Syncom Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-12-2024
- Paid Up Capital ₹ 0.10 M
as on 17-12-2024
- Company Age 20 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2020)
- Profit 743.52%
(FY 2020)
- Ebitda 5267.35%
(FY 2020)
- Net Worth 564.69%
(FY 2020)
- Total Assets 95.28%
(FY 2020)
About Syncom Biotech
The Corporate was formerly known as Synom Lifesciences Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Pratik Bankda and Pranav Bankda serve as directors at the Company.
- CIN/LLPIN
U24232MP2004PTC016541
- Company No.
016541
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Apr 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Syncom Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pratik Bankda  | Director | 23-Jul-2021 | Current |
| Pranav Bankda | Director | 09-Sep-2024 | Current |
Financial Performance of Syncom Biotech.
Syncom Biotech Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 743.52% increase in profit. The company's net worth Soared by an impressive increase of 564.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Syncom Biotech?
In 2019, Syncom Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Novita Healthcare Private LimitedActive 6 years 6 monthsPratik Bankda and Pranav Bankda are mutual person
- Indore Institutional Clothings Private LimitedActive 16 years 2 months
Pratik Bankda is a mutual person
- Novita Pharmaceutical Private LimitedActive 3 years 8 months
Pratik Bankda and Pranav Bankda are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Syncom Biotech?
Syncom Biotech has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Syncom Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Syncom Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
